"lung adenocarcinoma patients" trang 2 - tải miễn phí từ tailieunhanh
Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation

Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation
13    55    1
Gene alternation of cerebrospinal fuid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing

Gene alternation of cerebrospinal fuid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing
8    23    1
Associations of IFT20 and GM130 protein expressions with clinicopathological features and survival of patients with lung adenocarcinoma

Associations of IFT20 and GM130 protein expressions with clinicopathological features and survival of patients with lung adenocarcinoma
12    13    1
Epidermal growth factor receptor gene mutations in patients with lung adenocarcinoma differ by frequency and type between Uighur and Han ethnic groups in Xinjiang Autonomous Region

Epidermal growth factor receptor gene mutations in patients with lung adenocarcinoma differ by frequency and type between Uighur and Han ethnic groups in Xinjiang Autonomous Region
5    10    1
Establishing a prognostic model based on immune-related genes and identification of BIRC5 as a potential biomarker for lung adenocarcinoma patients

Establishing a prognostic model based on immune-related genes and identification of BIRC5 as a potential biomarker for lung adenocarcinoma patients
20    1    1
The role of CD28 in the prognosis of young lung adenocarcinoma patients

The role of CD28 in the prognosis of young lung adenocarcinoma patients
11    29    1
ALK-rearranged lung squamous cell carcinoma responding to alectinib: A case report and review of the literature

ALK-rearranged lung squamous cell carcinoma responding to alectinib: A case report and review of the literature
5    69    1
Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients
10    50    1
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
8    74    0
Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification

Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification
10    54    1
Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma

Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma
9    32    1
EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: A systematic review and metaanalysis

EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: A systematic review and metaanalysis
6    42    1
Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapynaïve non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR

Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapynaïve non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR
7    39    1
MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: Implications on prognostic immunological biomarker and vaccine design

MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: Implications on prognostic immunological biomarker and vaccine design
9    54    1
Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: A multicenter retrospective study from Japan

Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: A multicenter retrospective study from Japan
6    2    1
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
8    58    1
A systematic analysis of immune genes and overall survival in cancer patients

A systematic analysis of immune genes and overall survival in cancer patients
9    70    0
Risk of second primary Cancer among bladder Cancer patients: A populationbased cohort study in Korea

Risk of second primary Cancer among bladder Cancer patients: A populationbased cohort study in Korea
9    86    1